Immunotherapeutic Potential of Mycobacterium indicus pranii Against Tuberculosis

  • Sangeeta BhaskarEmail author
  • Bindu Singh


Mycobacterium indicus pranii (MIP), a nonpathogenic saprophytic mycobacterium, is potential tuberculosis (TB) vaccine candidate as it shares a large number of cross-reactive antigens with M.tb and has demonstrated unique ability for immunomodulation. Studies in animal models of TB have demonstrated its significant prophylactic and therapeutic efficacy against TB. The immunological aspects of MIP-mediated protection include induction of Th1 and Th17 type of response, activation of macrophage effector functions, and CD4+ T cell activation along with enhanced CD8+ T cell cytotoxic activity, thereby resulting in inhibition of the intracellular growth and multiplication of M.tb. When used as a booster to BCG vaccine, MIP conferred higher protection in animal models of TB. Protective efficacy of killed MIP vaccine has been established in clinical trials. Immunotherapeutic potential of this vaccine is confirmed in a recently conducted multicentric clinical trial in category II TB patients, having advanced disease, and was difficult to treat. Moreover, practical implementation of MIP as TB vaccine has a major advantage as it is a cost-effective vaccination strategy for effective control of TB with no adverse effects.


MIP Tuberculosis Vaccine 

List of Abbreviations


Mycobacterium indicus pranii


Mycobacterium leprae




Mycobacterium avium complex




Mycobacterium bovis










Antitubercular treatment


Pulmonary TB


  1. Ahmad F, Mani J, Kumar P, Haridas S, Upadhyay P, Bhaskar S (2011) Activation of anti-tumor immune response and reduction of regulatory T Cells with Mycobacterium indicus pranii (MIP) therapy in tumor bearing mice. PLoS ONE 6(9):e25424CrossRefGoogle Scholar
  2. Ahmed N, Saini V, Raghuvanshi S, Khurana JP, Tyagi AK (2007) Molecular analysis of a leprosy immunotherapeutic bacillus provides insights into mycobacterium evolution. PLoS ONE 2(10):e968CrossRefGoogle Scholar
  3. Gupta A, Geetha N, Mani J, Upadhyay P, Katoch VM, Natrajan M, Gupta UD, Bhaskar S (2009) Immunogenicity and protective efficacy of “Mycobacterium w” against Mycobacterium tuberculosis in mice immunized with live versus heat-killed M.w by the aerosol or parenteral route. Infect Immun 77(1):223–231CrossRefGoogle Scholar
  4. Gupta A, Ahmad FJ, Ahmad F, Gupta UD, Natarajan M, Katoch V, Bhaskar S (2012a) Efficacy of Mycobacterium indicus pranii immunotherapy as an adjunct to chemotherapy for tuberculosis and underlying immune responses in the lung. PLoS ONE 7(7):e39215CrossRefGoogle Scholar
  5. Gupta A, Ahmad FJ, Ahmad F, Gupta UD, Natarajan M, Katoch VM, Bhaskar S (2012b) Protective efficacy of Mycobacterium indicus pranii against tuberculosis and underlying local lung immune responses in guinea pig model. Vaccine 30(43):6198–6209CrossRefGoogle Scholar
  6. Katoch K, Singh P, Adhikari T, Benara SK, Singh HB, Chauhan DS, Sharma VD, Lavania M, Sachan AS, Katoch VM (2008) Potential of Mw as a prophylactic vaccine against pulmonary tuberculosis. Vaccine 26:1228–1234CrossRefGoogle Scholar
  7. Rahman SA, Singh Y, Kohli S, Ahmad J, Ehtesham NZ, Tyagi AK, Hasnain SE (2014) Comparative analyses of nonpathogenic, opportunistic and totally pathogenic mycobacteria reveal genomic and biochemical variabilities and highlight the survival attributes of Mycobacterium tuberculosis. mBio 5(6):02020–02014CrossRefGoogle Scholar
  8. Rakshit S, Ponnusamy M, Papanna S, Saha B, Ahmed A, Nandi D (2012) Immunotherapeutic efficacy of Mycobacterium indicuspranii in eliciting anti-tumor T cell responses: critical roles of IFNγ. Int J Cancer 130(4):865–875CrossRefGoogle Scholar
  9. Saini V, Raghuvanshi S, Talwar GP, Ahmed N, Khurana JP, Hasnain SE, Tyagi A, Tyagi AK (2009) Polyphasic taxonomic analysis establishes Mycobacterium indicus pranii as a distinct species. PLoS ONE 4(7):e6263CrossRefGoogle Scholar
  10. Saini V, Raghuvanshi S, Niyaz A, Khurana JP, Hasnain SE, Tyagi A, Tyagi AK (2012) Massive gene acquisitions in Mycobacterium indicus pranii provide a perspective on mycobacterial evolution. Nucleic Acids Res 40:10832–10850CrossRefGoogle Scholar
  11. Saqib M, Khatri R, Singh B, Gupta A, Bhaskar S (2016) Mycobacterium indicus pranii as a booster vaccine enhances BCG induced immunity and confers higher protection in animal models of tuberculosis. Tuberculosis 101:164e173CrossRefGoogle Scholar
  12. Sharma P, Mukherjee R, Talwar GP, Sarathchandra KG, Singh P (2005) Immunoprophylactic effects of the anti-leprosy Mw vaccine in household contacts of leprosy patients: clinical field trials with a follow up of 8–10 years. Lepr Rev 76:127–143PubMedGoogle Scholar
  13. Singh IG, Mukherjee R, Talwar GP (1991) Resistance to intravenous inoculation of Mycobacterium tuberculosis H37Rv in mice of different inbred strains following immunization with a leprosy vaccine based on Mycobacterium w. Vaccine 9:10–14CrossRefGoogle Scholar
  14. Singh Y, Kohli S, Sowpati DT, Rahman SA, Tyagi AK, Hasnain SE (2014) Gene cooption in mycobacteria and search for virulence attributes: comparative proteomic analyses of Mycobacterium tuberculosis, Mycobacterium indicus pranii and other mycobacteria. Int J Med Microbiol 304(5–6):742–748CrossRefGoogle Scholar
  15. Singh B, Saqib M, Gupta A, Kumar P, Bhaskar S (2017) Autophagy induction by Mycobacterium indicus pranii promotes Mycobacterium tuberculosis clearance from RAW 264.7 macrophages. PLoS ONE 12(12):e0189606CrossRefGoogle Scholar
  16. Talwar GP, Zaheer SA, Mukherjee R, Walia R, Suresh NR (1990) Immunotherapeutic effects of a vaccine based on a saprophytic cultivable mycobacterium, Mycobacterium w in multi-bacillary leprosy patients. Vaccine 8:121–129CrossRefGoogle Scholar
  17. Talwar GP (1999) An immunotherapeutic vaccine for multi-bacillary leprosy. Int Rev Immunol 18(3):229–249CrossRefGoogle Scholar
  18. Yadava A, Suresh NR, Zaheer S, Talwar GP, Mukherjee R (1991) T-Cell responses to fractionated antigens of Mycobacterium w, a candidate anti-leprosy vaccine, in leprosy patients. Scand J Immunol 34(1):23–31CrossRefGoogle Scholar
  19. Zaheer SA, Mukherjee R, Ramkumar B, Misra RS, Talwar GP (1993) Combined multidrug and Mycobacterium w vaccine therapy in patients with multibacillary leprosy. J Infect Dis 167:401–410CrossRefGoogle Scholar

Copyright information

© Springer Nature Singapore Pte Ltd. 2019

Authors and Affiliations

  1. 1.Product Development Cell-INational Institute of ImmunologyNew DelhiIndia

Personalised recommendations